189 related articles for article (PubMed ID: 17272741)
1. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation.
Ladenvall C; Gils A; Jood K; Blomstrand C; Declerck PJ; Jern C
Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):955-62. PubMed ID: 17272741
[TBL] [Abstract][Full Text] [Related]
2. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
Xu CW; Wang LL; Wu XB; Zhao JJ; Du YM; Jiang CY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):438-42. PubMed ID: 18683146
[TBL] [Abstract][Full Text] [Related]
3. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.
de Bruijne EL; Darwish Murad S; de Maat MP; Tanck MW; Haagsma EB; van Hoek B; Rosendaal FR; Janssen HL; Leebeek FW;
Thromb Haemost; 2007 Feb; 97(2):181-5. PubMed ID: 17264944
[TBL] [Abstract][Full Text] [Related]
4. Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke.
Rooth E; Wallen H; Antovic A; von Arbin M; Kaponides G; Wahlgren N; Blombäck M; Antovic J
Blood Coagul Fibrinolysis; 2007 Jun; 18(4):365-70. PubMed ID: 17473579
[TBL] [Abstract][Full Text] [Related]
5. Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study.
Kozian DH; Lorenz M; März W; Cousin E; Mace S; Deleuze JF
Thromb Haemost; 2010 May; 103(5):976-83. PubMed ID: 20216989
[TBL] [Abstract][Full Text] [Related]
6. Serum C-reactive protein concentration and genotype in relation to ischemic stroke subtype.
Ladenvall C; Jood K; Blomstrand C; Nilsson S; Jern C; Ladenvall P
Stroke; 2006 Aug; 37(8):2018-23. PubMed ID: 16809555
[TBL] [Abstract][Full Text] [Related]
7. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis.
Martini CH; Brandts A; de Bruijne EL; van Hylckama Vlieg A; Leebeek FW; Lisman T; Rosendaal FR
Br J Haematol; 2006 Jul; 134(1):92-4. PubMed ID: 16803573
[TBL] [Abstract][Full Text] [Related]
8. Association of genotypes of thrombin-activatable fibrinolysis inhibitors with thrombotic microangiopathies--a pilot study.
Sucker C; Hetzel GR; Farokhzad F; Dahhan F; Schmitz M; Kurschat C; Grabensee B; Maruhn-Debowski B; Zotz R; Scharf R
Nephrol Dial Transplant; 2007 May; 22(5):1347-50. PubMed ID: 17327284
[TBL] [Abstract][Full Text] [Related]
9. Haplotypes of TAFI gene and the risk of cerebral venous thrombosis--a case-control study.
Orikaza CM; Morelli VM; Matos MF; Lourenço DM
Thromb Res; 2014 Jan; 133(1):120-4. PubMed ID: 24252537
[TBL] [Abstract][Full Text] [Related]
10. Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome.
Tàssies D; Roqué M; Monteagudo J; Martorell T; Sionis A; Arzamendi D; Heras M; Reverter JC
Thromb Res; 2009 Nov; 124(5):614-8. PubMed ID: 19699511
[TBL] [Abstract][Full Text] [Related]
11. Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis.
Franco RF; Fagundes MG; Meijers JC; Reitsma PH; Lourenço D; Morelli V; Maffei FH; Ferrari IC; Piccinato CE; Silva WA; Zago MA
Haematologica; 2001 May; 86(5):510-7. PubMed ID: 11410415
[TBL] [Abstract][Full Text] [Related]
12. A-G-4G haplotype of PAI-1 gene polymorphisms -844 G/A, HindIII G/C, and -675 4G/5G is associated with increased risk of ischemic stroke caused by small vessel disease.
Adamski MG; Turaj W; Slowik A; Wloch-Kopec D; Wolkow P; Szczudlik A
Acta Neurol Scand; 2009 Aug; 120(2):94-100. PubMed ID: 19154538
[TBL] [Abstract][Full Text] [Related]
13. Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population.
Santamaría A; Borrell M; Oliver A; Ortín R; Forner R; Coll I; Mateo J; Souto JC; Fontcuberta J
Am J Hematol; 2004 Aug; 76(4):348-52. PubMed ID: 15282667
[TBL] [Abstract][Full Text] [Related]
14. Thrombin-activatable fibrinolysis inhibitor polymorphisms and recurrent pregnancy loss.
Masini S; Ticconi C; Gravina P; Tomassini M; Pietropolli A; Forte V; Federici G; Piccione E; Bernardini S
Fertil Steril; 2009 Aug; 92(2):694-702. PubMed ID: 18774564
[TBL] [Abstract][Full Text] [Related]
15. Plasma thrombin-activatable fibrinolysis inhibitor as an indicator of inflammation and disease severity in acute pancreatitis.
Sayilir A; Beyazit Y; Yesil Y; Albayrak M; Ekiz F; Celik T; Suvak B; Torun S; Ibiş M
Clin Res Hepatol Gastroenterol; 2012 Oct; 36(5):498-504. PubMed ID: 22230218
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor alpha (ESR1) PvuII and XbaI gene polymorphisms in ischemic stroke in a Hungarian population.
Molvarec A; Széplaki G; Kovács M; Széplaki Z; Fazakas A; Prohászka Z; Füst G; Karádi I
Clin Chim Acta; 2007 Jul; 382(1-2):100-5. PubMed ID: 17493601
[TBL] [Abstract][Full Text] [Related]
17. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer.
Chengwei X; Xiaoli M; Yuan Z; Li P; Shengjiang W; Chao Y; Yunshan W
Blood Coagul Fibrinolysis; 2013 Oct; 24(7):698-703. PubMed ID: 23624357
[TBL] [Abstract][Full Text] [Related]
18. No evidence for an association between ABO blood group and overall ischemic stroke or any of the major etiologic subtypes.
Hanson E; Karlsson S; Jood K; Nilsson S; Blomstrand C; Jern C
Thromb Res; 2012 Sep; 130(3):339-42. PubMed ID: 22482829
[TBL] [Abstract][Full Text] [Related]
19. [Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients].
Kemona-Chetnik I; Kowal K; Kucharewicz I; Pampuch A; Bodzenta-Lukaszyk A
Przegl Lek; 2006; 63(12):1281-5. PubMed ID: 17642140
[TBL] [Abstract][Full Text] [Related]
20. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
Paola Cellai A; Antonucci E; Alessandrello Liotta A; Fedi S; Marcucci R; Falciani M; Giglioli C; Abbate R; Prisco D
Thromb Res; 2006; 118(4):495-500. PubMed ID: 16318869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]